Clinical trials: Allergic
Perennial Allergic Rhinitis With Seasonal Variation
The Efficacy & Safety of the UAS Immunotherapy Protocol
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
- Trial name
- NCT01699659
- Testing
- allergen immunotherapy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Allergic Rhinoconjunctivitis
Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract
As part of the registration plan of our products and after performing a Phase I study the present trial has been designed to compare the efficacy of 5 different doses of subcutaneous immunotherapy in depot presentation.
- Trial name
- NCT01564017
- Testing
- Allergovac depot
- Where
- 12 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Roxall Medicina España S.A
Allergic Rhinitis
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
- Trial name
- NCT00929968
- Testing
- VAK694, Fluticasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Seasonal Allergic Rhinitis
Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)
This study will evaluate the efficacy and safety of montelukast (MK-0476) in the treatment of Japanese pediatric participants with seasonal allergic rhinitis (SAR).
- Trial name
- NCT01857063
- Testing
- Montelukast
- Volunteers
- 220 people
- Sponsor
- Organon and Co
Hay Fever
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients…
- Trial name
- NCT02560948
- Testing
- gpASIT+TM
- Where
- 3 sites in Belgium, Italy and 1 more
- Volunteers
- 554 people
- Sponsor
- BioTech Tools S.A.
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Food Hypersensitivity, Hypersensitivity
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00850668
- Testing
- E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Allertein Therapeutics, LLC
Rhinitis, Allergic, Seasonal
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the…
- Trial name
- NCT00197262
- Testing
- GW685698X Aqueous Nasal Spray
- Where
- 18 sites in United States
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Cutaneous Patch, Dermatitis
Evaluation of Irritancy/Allergic Sensitivity to Natural Personal-care Products by Patch Tests
The purpose of the study is to determine if any of Mother's Choice' all-natural personal-care products cause either irritation or allergic reaction when applied to both normal or sensitive skin.
- Conditions
- Cutaneous Patch, Dermatitis, Allergy, Cosmetic Allergy
- Trial name
- NCT01816542
- Testing
- patch tests on healthy skin
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mother's Choice Ltd
Persistent Allergic Rhinitis
A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years
The goal of this clinical trial is to learn whether DEP114 is effective in treating acute exacerbations of persistent allergic rhinitis in children aged 6 to less than 12 years. The study will also evaluate the safety of DEP114.
- Trial name
- DESPRIN (NCT07835074)
- Testing
- DEP114, Desloratadine
- Volunteers
- 316 people
- Sponsor
- EMS
Allergic Rhinoconjunctivitis
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study was to assess safety and tolerability of 3 different…
- Trial name
- NCT01489020
- Testing
- subcutaneous immunotherapy with DPT extract
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Roxall Medicina España S.A
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00133146
- Testing
- Grass MATA MPL
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Allergy Therapeutics
Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)
This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days…
- Trial name
- NCT00794846
- Testing
- Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec)
- Volunteers
- 124 people
- Sponsor
- Organon and Co
Dermatitis, Allergy
Human Repeated Insult Patch Test
Repeated insult patch test on healthy males and females to determine potential contact irritation or contact allergy in the skin
- Conditions
- Dermatitis, Allergy, Contact Allergy
- Trial name
- NCT03474874
- Testing
- NeoMatriX Collagen Dressing
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- NeXtGen Biologics, Inc.
Allergic Rhinitis
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic…
- Trial name
- NCT03558997
- Testing
- Dupilumab, Timothy Grass SCIT
- Where
- 17 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Regeneron Pharmaceuticals
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
- Trial name
- NCT00883168
- Testing
- azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 1,791 people
- Sponsor
- Meda Pharmaceuticals
Seasonal Allergic Rhinitis
New Nasal Applicator / New Formulation - User Study
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
- Trial name
- NCT00641979
- Testing
- budesonide
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Asthma
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma
This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma.
- Trial name
- NCT01501942
- Testing
- AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide, Buffered Saline
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AIM Therapeutics Inc.
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research